ES2148486T3 - Intermediarios de cloropirimidina. - Google Patents

Intermediarios de cloropirimidina.

Info

Publication number
ES2148486T3
ES2148486T3 ES95907107T ES95907107T ES2148486T3 ES 2148486 T3 ES2148486 T3 ES 2148486T3 ES 95907107 T ES95907107 T ES 95907107T ES 95907107 T ES95907107 T ES 95907107T ES 2148486 T3 ES2148486 T3 ES 2148486T3
Authority
ES
Spain
Prior art keywords
chloropyrimidine
intermediaries
processes
pirimidine
aminopurines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95907107T
Other languages
English (en)
Inventor
Susan Mary Daluge
Michael Tolar Martin
Michelle Joanne Ferry Fugett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10749873&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2148486(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of ES2148486T3 publication Critical patent/ES2148486T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Catalysts (AREA)
  • Indole Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Liquid Crystal Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A CIERTOS INTERMEDIARIOS NUEVOS DE PIRIMIDINA Y SUS SALES, PROCESOS PARA SU PREPARACION Y PROCESOS PARA SU CONVERSION A 9-SUSTITUIDO-2-AMINOPURINAS LAS CUALES SON UTILES EN LA TERAPIA MEDICA.
ES95907107T 1994-02-04 1995-02-03 Intermediarios de cloropirimidina. Expired - Lifetime ES2148486T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9402161A GB9402161D0 (en) 1994-02-04 1994-02-04 Chloropyrimidine intermediates

Publications (1)

Publication Number Publication Date
ES2148486T3 true ES2148486T3 (es) 2000-10-16

Family

ID=10749873

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95907107T Expired - Lifetime ES2148486T3 (es) 1994-02-04 1995-02-03 Intermediarios de cloropirimidina.

Country Status (27)

Country Link
US (8) US6448403B1 (es)
EP (1) EP0741710B1 (es)
JP (1) JP3670012B2 (es)
KR (1) KR100355983B1 (es)
CN (2) CN1161343C (es)
AT (1) ATE192742T1 (es)
AU (1) AU690203B2 (es)
BR (1) BR9506667A (es)
DE (1) DE69516847T2 (es)
DK (1) DK0741710T3 (es)
ES (1) ES2148486T3 (es)
FI (1) FI112477B (es)
GB (1) GB9402161D0 (es)
GR (1) GR3033850T3 (es)
HU (1) HU223096B1 (es)
IL (1) IL112539A (es)
MX (1) MX9603091A (es)
MY (1) MY113775A (es)
NO (1) NO310819B1 (es)
NZ (1) NZ278948A (es)
PL (1) PL183885B1 (es)
PT (1) PT741710E (es)
RU (1) RU2140913C1 (es)
SG (1) SG47918A1 (es)
TW (1) TW390877B (es)
WO (1) WO1995021161A1 (es)
ZA (1) ZA95884B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9402161D0 (en) * 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
CA2145928C (en) * 1994-04-27 2007-10-09 Gerhard Stucky N-(2-amino-4,6-dichloropyrimidin-5-yl)formamide, and a process for its preparation
ZA9510482B (en) * 1994-12-12 1996-09-17 Smithkline Beecham Plc Pharmaceuticals
SK285228B6 (sk) * 1997-05-13 2006-09-07 Lonza Ag Spôsob výroby racemického alebo opticky aktívnehoderivátu 4-(hydroxymetyl)-2-cyklopenténu a racemicky N-butyryl-1-amino-4- (hydroxymetyl)-2-cyklopentén
GB9721780D0 (en) 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
AU2702899A (en) * 1997-10-24 1999-05-17 Glaxo Group Limited Process for preparing a chiral nucleoside analogue
EP1032573A1 (en) * 1997-11-12 2000-09-06 Glaxo Group Limited Process for preparing a chiral nucleoside analogue
CZ298144B6 (cs) 1997-11-27 2007-07-04 Lonza Ag Zpusob výroby (1S,4R)- nebo (1R,4S)-4-(2-amino-6-chlor-9-H-purin-9-yl)-2-cyklopenten-1-methanolu
ES2204798T3 (es) * 1998-12-21 2004-05-01 Lonza Ag Procedimiento para la preparacion de 2,5-diamino-4,6-dihalogenopirimidina.
CA2440809A1 (en) * 2001-03-01 2002-09-12 Conforma Therapeutics Corp. Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
WO2003037860A2 (en) * 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
US20070129334A1 (en) * 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
US6780635B2 (en) 2001-12-27 2004-08-24 Council Of Scientific And Industrial Research Process for the preparation of optically active azabicyclo heptanone derivatives
KR100573859B1 (ko) * 2002-07-15 2006-04-25 경동제약 주식회사 9-[4-아세톡시-3-(아세톡시메틸)부트-1-일]-2-아미노푸린의제조방법
US7560231B2 (en) * 2002-12-20 2009-07-14 Roche Molecular Systems, Inc. Mannitol and glucitol derivatives
EP1511750A1 (en) * 2003-04-30 2005-03-09 Teva Pharmaceutical Industries Ltd. Process for the preparation of famciclovir
WO2004103979A1 (ja) * 2003-05-26 2004-12-02 Sumitomo Chemical Company, Limited Ｎ－（２－アミノ－４，６－ジクロロピリミジン－５－イル）ホルムアミドの製造方法
KR100573860B1 (ko) * 2003-06-13 2006-04-25 경동제약 주식회사 2-아미노-9-(2-치환에틸)푸린을 이용한 9-[4-아세톡시-3-(아세톡시메틸)부트-1-일]-2-아미노푸린의 제조방법
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
KR100573861B1 (ko) * 2003-07-18 2006-04-25 경동제약 주식회사 2-아미노-9-(2-할로게노에틸)푸린 및 그 중간체로서의 2-아미노-6,8-디클로로-9-(2-히드록시에틸)푸린의 제조방법
GB0320738D0 (en) 2003-09-04 2003-10-08 Glaxo Group Ltd Novel process
EP1556383A1 (en) * 2003-09-04 2005-07-27 Teva Pharmaceutical Industries Ltd. Process for preparing famciclovir
MXPA06002997A (es) * 2003-09-18 2007-02-08 Conforma Therapeutics Corp Novedosos compuestos heterociclicos como inhibidores- hsp90.
DE102004002055A1 (de) * 2004-01-15 2005-08-11 Degussa Ag Verfahren zur Herstellung von 2-Amino-4,6-dichlor-5-formamidopyrimidin
EP2319925B1 (en) * 2004-08-16 2018-07-25 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of RTP801
AU2006230447A1 (en) * 2005-03-30 2006-10-05 Conforma Therapeutics Corporation Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors
GB2426247A (en) 2005-05-20 2006-11-22 Arrow Int Ltd Methods of preparing purine derivatives such as famciclovir
WO2007035963A2 (en) * 2005-09-23 2007-03-29 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
EP1857458A1 (en) * 2006-05-05 2007-11-21 SOLMAG S.p.A. Process for the preparation of abacavir
CN100465174C (zh) * 2006-06-13 2009-03-04 中国科学院上海有机化学研究所 制备光学纯阿巴卡韦的方法
WO2008072074A1 (en) * 2006-12-11 2008-06-19 Aurobindo Pharma Limited An improved process for the preparation of purine derivative
EP1939196A1 (en) * 2006-12-21 2008-07-02 Esteve Quimica, S.A. Process for the preparation of abacavir
WO2008155613A1 (en) * 2007-06-21 2008-12-24 Aurobindo Pharma Ltd An improved process for preparing purine derivative
EP2085397A1 (en) 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
LT3494972T (lt) 2010-01-27 2024-03-12 Viiv Healthcare Company Dolutegraviro ir lamivudino kompozicija živ infekcijai gydyti
CZ305457B6 (cs) * 2011-02-28 2015-09-30 Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
WO2014133085A1 (ja) 2013-02-27 2014-09-04 国立大学法人京都大学 がんの予防または治療用医薬組成物
CN104672239A (zh) * 2013-11-26 2015-06-03 上海迪赛诺化学制药有限公司 一种采用一锅法制备阿巴卡韦式v中间体的工艺
CN109456329B (zh) * 2018-11-19 2021-03-09 迪嘉药业集团有限公司 一种泛昔洛韦的制备方法
CN113292507B (zh) * 2021-06-25 2022-07-19 潍坊奥通药业有限公司 一种2-氨基-6-氯鸟嘌呤及其中间体的制备方法
CN116239596A (zh) * 2022-11-28 2023-06-09 安徽贝克制药股份有限公司 一种阿巴卡韦杂质a的制备方法及用途
CN118852029B (zh) * 2024-09-23 2025-02-07 苏州开元民生科技股份有限公司 一种制备2-氨基-4,6-二氯-5-甲酰胺基嘧啶的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0141927B1 (en) 1983-08-18 1991-10-30 Beecham Group Plc Antiviral guanine derivatives
EP0182024B1 (en) 1984-09-20 1991-04-03 Beecham Group Plc Purine derivatives and their pharmaceutical use
MY101126A (en) * 1985-12-13 1991-07-31 Beecham Group Plc Novel compounds
US4965270A (en) 1987-05-30 1990-10-23 Beecham Group P.L.C. Purine derivatives
GB8724765D0 (en) * 1987-10-22 1987-11-25 Beecham Group Plc Process
US5631370A (en) 1988-01-20 1997-05-20 Regents Of The University Of Minnesota Optically-active isomers of dideoxycarbocyclic nucleosides
US4916224A (en) 1988-01-20 1990-04-10 Regents Of The University Of Minnesota Dideoxycarbocyclic nucleosides
GB2243609B (en) * 1988-01-20 1992-03-11 Univ Minnesota Dideoxydidehydrocarbocyclic pyrimidines
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
GB8916698D0 (en) 1989-07-21 1989-09-06 Beecham Group Plc Novel process
GB8918827D0 (en) 1989-08-17 1989-09-27 Beecham Group Plc Novel compounds
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
SK279618B6 (sk) * 1992-01-22 1999-01-11 Lonza A.G. (Dir.:Basel) N-5-chránené 2,5-diamino-4,6-dichlórpyrimidíny a s
JPH05320143A (ja) * 1992-03-18 1993-12-03 Mochida Pharmaceut Co Ltd 新規ピリミジン誘導体
GB9402161D0 (en) * 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
CA2145928C (en) * 1994-04-27 2007-10-09 Gerhard Stucky N-(2-amino-4,6-dichloropyrimidin-5-yl)formamide, and a process for its preparation

Also Published As

Publication number Publication date
KR100355983B1 (ko) 2002-12-28
US5917042A (en) 1999-06-29
US6448403B1 (en) 2002-09-10
CN1139924A (zh) 1997-01-08
BR9506667A (pt) 1997-09-16
US20030187263A1 (en) 2003-10-02
HU223096B1 (hu) 2004-03-29
CN1105109C (zh) 2003-04-09
ATE192742T1 (de) 2000-05-15
DK0741710T3 (da) 2000-08-14
HU9602114D0 (en) 1996-09-30
CN1388123A (zh) 2003-01-01
HUT75300A (en) 1997-05-28
TW390877B (en) 2000-05-21
PT741710E (pt) 2000-09-29
CN1161343C (zh) 2004-08-11
US6555687B1 (en) 2003-04-29
JP3670012B2 (ja) 2005-07-13
NO963239D0 (no) 1996-08-02
RU2140913C1 (ru) 1999-11-10
NO310819B1 (no) 2001-09-03
DE69516847T2 (de) 2000-10-26
GB9402161D0 (en) 1994-03-30
FI112477B (fi) 2003-12-15
AU690203B2 (en) 1998-04-23
US5917041A (en) 1999-06-29
FI963070L (fi) 1996-08-02
JPH09508412A (ja) 1997-08-26
FI963070A0 (fi) 1996-08-02
NO963239L (no) 1996-10-02
SG47918A1 (en) 1998-04-17
US6552193B1 (en) 2003-04-22
MY113775A (en) 2002-05-31
EP0741710A1 (en) 1996-11-13
US6087501A (en) 2000-07-11
ZA95884B (en) 1996-08-05
IL112539A (en) 2000-08-31
DE69516847D1 (de) 2000-06-15
MX9603091A (es) 1998-01-31
GR3033850T3 (en) 2000-10-31
NZ278948A (en) 1998-01-26
PL183885B1 (pl) 2002-07-31
HK1004087A1 (en) 1998-11-13
EP0741710B1 (en) 2000-05-10
US20020173649A1 (en) 2002-11-21
US6870053B2 (en) 2005-03-22
IL112539A0 (en) 1995-05-26
WO1995021161A1 (en) 1995-08-10
PL315713A1 (en) 1996-11-25
AU1543895A (en) 1995-08-21

Similar Documents

Publication Publication Date Title
ES2148486T3 (es) Intermediarios de cloropirimidina.
ES2099056T3 (es) Cepas de lactobacillus de origen humano, sus composiciones y usos de las mismas.
SE8501709D0 (sv) Improvements in or relating to intrleukin therapy
FI973868A7 (fi) D2-vitamiini- tai D4-vitamiinijohdannaisten käyttö sekundaarisen hyper paratyreoosin hoitoon tarkoitettu lääkkeen valmistuksessa
ES2030409T3 (es) Procedimiento para preparar y purificar compuestos termolabiles .
HN1997000058A (es) Derivados indolicos utiles para terapia
BR9910671A (pt) 24-hidroxivitamina d, análogos e utilizações dos mesmos
ES2175519T3 (es) Uso de derivados de acido7-(2-oxa-5,8-diazabiciclo(4,3,0)non-8-8-il)-quinoloncarboxilico y-naftiridoncarboxilico para la fabricacion de un medicanto para la terapia de infecciones por helicobacter pylori y las enfermedades gastroduodenales asociadas con ellas.
ES2182874T3 (es) Procedimiento de tratamiento de las uñas.
ES2169147T3 (es) Derivados de beta-carbolina agonistas de la melatonina, sus procedimientos de preparacion y su utilizacion a titulo de medicamento.
HN1998000030A (es) 2-amino-6-(4fenoxi-2-sustituido)-piridinas sustituidas
AR012504A1 (es) Utilizacion de derivados de tetrahidropiridina, para la preparacion de medicamentos para el tratamiento de las enfermedades que provocan unadesmielinizacion.
ES2166051T3 (es) Productos intermedios y procedimiento para preparar olanzapina.
DE69521122D1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure-additions-salze
ES2156215T3 (es) Utilizacion de un conjugado en el tratamiento y/o diagnostico de enfermedades inflamatorias.
ES2079507T3 (es) Intermediarios para conjugados del acido difluoroglutamico con folatos y antifolatos para el tratamiento de enfermedades neoplasicas.
UY26265A1 (es) Compuestos calciolíticos
ES2077674T3 (es) Aumento de la produccion de proteinas en animales.
DE69000791D1 (de) Therapeutische mittel fuer metabolische knochenkrankheiten.
ES2045146T3 (es) Avermectinas etiladas.
ES2147863T3 (es) Nuevos procedimientos para preparar intermediarios de inhibidores del enzima conversor de la encefalinasa y de la angiotensina y sus intermediarios.
PT878195E (pt) Utilizacao de um composto 2-aroil-3-arilbenzo(b)tiofeno para a reducao de fibrinogenio
MX124B (es) Modelo de utilidad de sandalias ajustables desechables
ES2181160T3 (es) Derivados de 1,4-dihidropiridina y su utilizacion en terapia.
HN1998000014A (es) Metodo de purificacion de 1,3,5, trii sopropilbenceno

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 741710

Country of ref document: ES